<DOC>
	<DOC>NCT00317395</DOC>
	<brief_summary>Primary objective: To demonstrate the clinical efficacy of otamixaban (dose effect via 5 intravenous [IV] regimens) in patients with moderate-to-high-risk non-ST elevation acute coronary syndromes (ACS) and planned early invasive strategy. Secondary objectives: To evaluate safety and assess pharmacokinetics (PK) and pharmacodynamics (PD).</brief_summary>
	<brief_title>Study of Otamixaban Versus Unfractionated Heparin (UFH) and Eptifibatide in Non-ST Elevation Acute Coronary Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Acute Coronary Syndrome</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Calcium heparin</mesh_term>
	<mesh_term>Otamixaban</mesh_term>
	<mesh_term>Heparin</mesh_term>
	<mesh_term>Eptifibatide</mesh_term>
	<criteria>Ischemic discomfort at rest â‰¥ 10 minutes within 24 hours of randomization Electrocardiogram (ECG) criteria for nonST elevation ACS or cardiac enzyme elevation (&gt; upper limit of normal [ULN]) No ST elevation Myocardial Infarction (STEMI) Planned coronary angiography followed when indicated by a Percutaneous Coronary Intervention (PCI) on Day 1 to Day 3 Inability to undergo coronary angiography or PCI by Day 3 Prior PCI within 30 days Acute STEMI Cardiogenic shock Anticoagulant treatment for &gt; 24 hours prior to randomization Prior treatment with fondaparinux since ACS onset Requirement for oral anticoagulant (OAC) prior to Day 30 Creatinine clearance &lt; 30 ml/min</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>Non ST elevation Acute Coronary Syndrome</keyword>
	<keyword>Early invasive strategy</keyword>
	<keyword>Percutaneous Coronary Intervention</keyword>
</DOC>